Companies › Teva Branded Pharmaceutical Products R&D
6 active drug programs in 9 registered trials: 4 Phase 2, 3 Phase 1, 2 Phase 3; Immunology, Respiratory, Neurology, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TEV-56248 Fixed-dose combination of inhaled corticosteroid (fluticasone propionate) and beta-2 agoni | ADRB2 | Phase 3 | Asthma | Dec 2026 |
| Fluticasone Propionate Glucocorticoid receptor agonist | NR3C1 | Phase 3 | Asthma | – |
| TEV-56286 alpha-synuclein aggregation inhibitor | SNCA | Phase 2 | Multiple System Atrophy; Healthy Volunteers | Jan 2027 |
| TEV-48574 TNF-α antagonist monoclonal antibody (duvakitug) | TNF | Phase 2 | Crohn Disease | Jan 2027 |
| TEV-53408 | – | Phase 2 | Celiac Disease; Vitiligo | Sep 2027 |
| TEV-56278 | – | Phase 1 | Advanced Solid Tumors | May 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06664619 | Fluticasone Propionate | Phase 3 | Asthma | Respiratory | Oct 2026 |
| NCT06052267 | TEV-56248 | Phase 3 | Asthma | Respiratory | Dec 2026 |
| NCT07674940 | TEV-56286 | Phase 1 | Healthy Volunteers | Other | Jan 2027 |
| NCT05668013 | TEV-48574 | Phase 2 | Crohn Disease | Immunology | Jan 2027 |
| NCT06807463 | TEV-53408 | Phase 2 | Celiac Disease | Gastroenterology | Sep 2027 |
| NCT06568237 | TEV-56286 | Phase 2 | Multiple System Atrophy | Neurology | Sep 2027 |
| NCT06625177 | TEV-53408 | Phase 1 | Vitiligo | Immunology | Apr 2028 |
| NCT07197866 | TEV-56286 | Phase 2 | Multiple System Atrophy | Neurology | May 2029 |
| NCT06480552 | TEV-56278 | Phase 1 | Advanced Solid Tumors | Oncology | May 2029 |
Chiesi Farmaceutici AstraZeneca Corcept Therapeutics GSK AC Immune Regeneron Pharmaceuticals Roche XingImaging Lunan Better Pharmaceutical Actimed Therapeutics
Sunshine Guojian Pharmaceutical (Shanghai) Guangdong Hengrui Pharmaceutical Chiesi Farmaceutici Optinose US Pacira Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.